{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:20:44Z","timestamp":1788308444081,"version":"build-2803163510"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T00:00:00Z","timestamp":1550793600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Center for Excellence in Translational Research","award":["U19-AI109755"],"award-info":[{"award-number":["U19-AI109755"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Big Data to Knowledge","award":["MRF ES026835"],"award-info":[{"award-number":["MRF ES026835"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"DOI":"10.1093\/jac\/dkz048","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T16:28:54Z","timestamp":1548865734000},"page":"1477-1483","source":"Crossref","is-referenced-by-count":55,"title":["Rifampicin and rifabutin resistance in 1003 Mycobacterium tuberculosis clinical isolates"],"prefix":"10.1093","volume":"74","author":[{"given":"Maha R","family":"Farhat","sequence":"first","affiliation":[{"name":"Department of Biomedical Informatics, Harvard Medical School, 10 Shattuck Street, Boston, MA, USA"},{"name":"Division of Pulmonary and Critical Care, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaimie","family":"Sixsmith","sequence":"additional","affiliation":[{"name":"Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Calderon","sequence":"additional","affiliation":[{"name":"Socios en Salud, Calle Los Geranios 312, Lince, Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan D","family":"Hicks","sequence":"additional","affiliation":[{"name":"Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M","family":"Fortune","sequence":"additional","affiliation":[{"name":"Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Murray","sequence":"additional","affiliation":[{"name":"Department of Global Health and Social Medicine, Harvard Medical School, 641 Huntington Avenue, Boston, MA, USA"},{"name":"Division of Global Health Equity, Brigham and Women\u2019s Hospital, 75 Francis Street, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,2,21]]},"reference":[{"key":"2019051708103748000_dkz048-B1","volume-title":"Global Tuberculosis Report 2016","year":"2016"},{"key":"2019051708103748000_dkz048-B2","volume-title":"Global Tuberculosis Report 2017","year":"2017"},{"key":"2019051708103748000_dkz048-B3","doi-asserted-by":"crossref","first-page":"e00812","DOI":"10.1128\/mBio.00812-17","article-title":"The new Xpert MTB\/RIF Ultra: improving detection of Mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care testing","volume":"8","author":"Chakravorty","year":"2017","journal-title":"mBio"},{"key":"2019051708103748000_dkz048-B4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/jac\/dkt358","article-title":"Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis","volume":"69","author":"Nebenzahl-Guimaraes","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2019051708103748000_dkz048-B5","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/ng.2743","article-title":"Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl-\u03b2-d-arabinose biosynthetic and utilization pathway genes","volume":"45","author":"Safi","year":"2013","journal-title":"Nat Genet"},{"key":"2019051708103748000_dkz048-B6","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1128\/JCM.02775-15","article-title":"Gyrase mutations are associated with variable levels of fluoroquinolone resistance in Mycobacterium tuberculosis","volume":"54","author":"Farhat","year":"2016","journal-title":"J Clin Microbiol"},{"key":"2019051708103748000_dkz048-B7","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1164\/rccm.201510-2091OC","article-title":"Genetic determinants of drug resistance in Mycobacterium tuberculosis and their diagnostic value","volume":"194","author":"Farhat","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2019051708103748000_dkz048-B8","doi-asserted-by":"crossref","first-page":"10063.","DOI":"10.1038\/ncomms10063","article-title":"Rapid antibiotic-resistance predictions from genome sequence data for Staphylococcus aureus and Mycobacterium tuberculosis","volume":"6","author":"Bradley","year":"2015","journal-title":"Nat Commun"},{"key":"2019051708103748000_dkz048-B9","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1473-3099(15)00062-6","article-title":"Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study","volume":"15","author":"Walker","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2019051708103748000_dkz048-B10","doi-asserted-by":"crossref","first-page":"e59414.","DOI":"10.1371\/journal.pone.0059414","article-title":"The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks","volume":"8","author":"Sirgel","year":"2013","journal-title":"PLoS One"},{"key":"2019051708103748000_dkz048-B11","volume-title":"Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes: Approved Standard M24-A","year":"2003"},{"key":"2019051708103748000_dkz048-B12","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S2213-2600(16)30433-7","article-title":"Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study","volume":"5","author":"Dheda","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2019051708103748000_dkz048-B13","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2019051708103748000_dkz048-B14","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.rmed.2012.10.021","article-title":"The efficacy of rifabutin for rifabutin-susceptible, multidrug-resistant tuberculosis","volume":"107","author":"Jo","year":"2013","journal-title":"Respir Med"},{"key":"2019051708103748000_dkz048-B15","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1093\/clinids\/22.Supplement_1.S50","article-title":"Use of rifabutin in the treatment of pulmonary tuberculosis","volume":"22","author":"Grassi","year":"1996","journal-title":"Clin Infect Dis"},{"key":"2019051708103748000_dkz048-B16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ijid.2017.10.013","article-title":"Treatment outcomes of rifabutin-containing regimens for rifabutin-sensitive multidrug-resistant pulmonary tuberculosis","volume":"65","author":"Lee","year":"2017","journal-title":"Int J Infect Dis"},{"key":"2019051708103748000_dkz048-B17","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1128\/JCM.00691-14","article-title":"Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis","volume":"52","author":"Jamieson","year":"2014","journal-title":"J Clin Microbiol"},{"key":"2019051708103748000_dkz048-B18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.diagmicrobio.2016.01.019","article-title":"Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex","volume":"85","author":"Berrada","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2019051708103748000_dkz048-B19","first-page":"408","article-title":"In vitro activity of rifabutin and rifampin against clinical isolates of Mycobacterium tuberculosis in Taiwan","volume":"99","author":"Chien","year":"2000","journal-title":"J Formos Med Assoc"},{"key":"2019051708103748000_dkz048-B20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0041-3879(87)90053-5","article-title":"In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria","volume":"68","author":"Dickinson","year":"1987","journal-title":"Tubercle"},{"key":"2019051708103748000_dkz048-B21","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1179\/joc.2005.17.4.380","article-title":"Incidence of cross resistance between rifampicin and rifabutin in Mycobacterium tuberculosis strains in Izmir, Turkey","volume":"17","author":"Senol","year":"2005","journal-title":"J Chemother"},{"key":"2019051708103748000_dkz048-B22","first-page":"164","article-title":"Investigation of cross-resistance between rifampin and rifabutin in Mycobacterium tuberculosis complex strains","volume":"6","author":"Uzun","year":"2002","journal-title":"Int J Tuberc Lung Dis"},{"key":"2019051708103748000_dkz048-B23","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1128\/AAC.42.7.1853","article-title":"Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis","volume":"42","author":"Williams","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2019051708103748000_dkz048-B24","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.tube.2011.05.002","article-title":"Rifamycin inhibition of WT and Rif-resistant Mycobacterium tuberculosis and Escherichia coli RNA polymerases in vitro","volume":"91","author":"Gill","year":"2011","journal-title":"Tuberculosis (Edinb)"},{"key":"2019051708103748000_dkz048-B25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/ije\/dyx171","article-title":"Protective effects of household-based TB interventions are robust to neighbourhood-level variation in exposure risk in Lima, Peru: a model-based analysis","volume":"47","author":"Zelner","year":"2018","journal-title":"Int J Epidemiol"},{"key":"2019051708103748000_dkz048-B26","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis: an update","volume":"74","author":"Alsultan","year":"2014","journal-title":"Drugs"},{"key":"2019051708103748000_dkz048-B27","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1101\/gr.111120.110","article-title":"Stampy: a statistical algorithm for sensitive and fast mapping of Illumina sequence reads","volume":"21","author":"Lunter","year":"2011","journal-title":"Genome Res"},{"key":"2019051708103748000_dkz048-B28","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/ng.3036","article-title":"Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications","volume":"46","author":"Rimmer","year":"2014","journal-title":"Nat Genet"},{"key":"2019051708103748000_dkz048-B29","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The Sequence Alignment\/Map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"2019051708103748000_dkz048-B30"},{"key":"2019051708103748000_dkz048-B31","doi-asserted-by":"crossref","first-page":"R46.","DOI":"10.1186\/gb-2014-15-3-r46","article-title":"Kraken: ultrafast metagenomic sequence classification using exact alignments","volume":"15","author":"Wood","year":"2014","journal-title":"Genome Biol"},{"key":"2019051708103748000_dkz048-B32","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1093\/molbev\/msr121","article-title":"MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods","volume":"28","author":"Tamura","year":"2011","journal-title":"Mol Biol Evol"},{"key":"2019051708103748000_dkz048-B33","doi-asserted-by":"crossref","first-page":"e0142951.","DOI":"10.1371\/journal.pone.0142951","article-title":"TGS-TB: total genotyping solution for Mycobacterium tuberculosis using short-read whole-genome sequencing","volume":"10","author":"Sekizuka","year":"2015","journal-title":"PLoS One"},{"key":"2019051708103748000_dkz048-B34","doi-asserted-by":"crossref","first-page":"4812.","DOI":"10.1038\/ncomms5812","article-title":"A robust SNP barcode for typing Mycobacterium tuberculosis complex strains","volume":"5","author":"Coll","year":"2014","journal-title":"Nat Commun"},{"key":"2019051708103748000_dkz048-B35","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/ng.811","article-title":"Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection","volume":"43","author":"Ford","year":"2011","journal-title":"Nat Genet"},{"key":"2019051708103748000_dkz048-B36","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMc1413930","article-title":"Detection of drug-resistant tuberculosis by Xpert MTB\/RIF in Swaziland","volume":"372","author":"Sanchez-Padilla","year":"2015","journal-title":"N Engl J Med"},{"key":"2019051708103748000_dkz048-B37","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/ng.2747","article-title":"Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis","volume":"45","author":"Farhat","year":"2013","journal-title":"Nat Genet"},{"key":"2019051708103748000_dkz048-B38","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1128\/AAC.46.8.2720-2722.2002","article-title":"Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis","volume":"46","author":"Palomino","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2019051708103748000_dkz048-B39","doi-asserted-by":"crossref","first-page":"e00344","DOI":"10.1128\/AAC.00344-18","article-title":"Validating a 14-drug microtiter plate containing bedaquiline and delamanid for large-scale research susceptibility testing of Mycobacterium tuberculosis","volume":"62","author":"Rancoita","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019051708103748000_dkz048-B40","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/429321","article-title":"Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis","volume":"40","author":"Weiner","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2019051708103748000_dkz048-B41","doi-asserted-by":"crossref","first-page":"61.","DOI":"10.1186\/2050-6511-15-61","article-title":"Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV-infected tuberculosis patients on lopinavir\/ritonavir-based antiretroviral therapy","volume":"15","author":"Naiker","year":"2014","journal-title":"BMC Pharmacol Toxicol"},{"key":"2019051708103748000_dkz048-B42","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1086\/606056","article-title":"Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis","volume":"49","author":"Boulanger","year":"2009","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/6\/1477\/28666594\/dkz048.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T08:11:40Z","timestamp":1558080700000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/74\/6\/1477\/5359497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,21]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,2,21]]},"published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkz048","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/425652","asserted-by":"object"}]},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,6]]},"published":{"date-parts":[[2019,2,21]]}}}